Showing 861-870 of 1576 results for "".
- Study Links Vitamin D Deficiency to Higher Risk of Dry Eye Diseasehttps://modernod.com/news/study-links-vitamin-d-deficiency-to-higher-risk-of-dry-eye-disease/2486076/Key Takeaways A large retrospective cohort study found that adults with vitamin D deficiency had a significantly higher risk of developing dry eye
- Atia Vision Closes $20M In Series D Financing to Fund Accommodating IOLhttps://modernod.com/news/atia-vision-closes-20m-in-series-d-financing-to-fund-accommodating-iol/2476533/Atia Vision, a Shifamed portfolio company developing a modular presbyopia-correcting accommodating IOL, announced initial closing of its committed $20 million Series D preferred stock
- MacuLogix Raises $38.7 Million in Series D Financing to Support Growthhttps://modernod.com/news/maculogix-raises-38-7-million-in-series-d-financing-led-by-vivo-capital/2479587/MacuLogix has completed a Series D round of financing totaling $38.7 million to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx
- Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institutehttps://modernod.com/news/glaukos-announces-pharmaceutical-development-agreement-with-d-western-therapeutics-institute/2479956/Glaukos announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide. Under the agreement, Glauko
- Atia Vision Closes Second Tranche Of $20M In Series D Financinghttps://modernod.com/news/atia-vision-closes-second-tranche-of-20m-in-series-d-financing/2477793/Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support ex
- Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officerhttps://modernod.com/news/outlook-therapeutics-appoints-c-russell-trenary-iii-as-president-and-chief-executive-officer/2479350/Outlook Therapeutics announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member o
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russiahttps://modernod.com/news/rayner-acquires-stake-in-reper-to-drive-rd-and-build-presence-in-russia/2476854/Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia. Terms of the deal were not disc